iBio FY2026: cash $88M, R&D up to $19.6M, IBIO-600 Phase 1 on track

iBio, Inc.

2026-FY EPS reported -$0.32 revenue$100,000

Revenue $0.1M (down from $0.4M); R&D expenses $19.6M vs $8.3M; G&A $10.6M.
Cash and investments $88.0M as of June 30, 2026; runway extended into FY2028.
IBIO-600 Phase 1 dosed 31 of 32 participants; advancing to multiple ascending dose.
IBIO-610 and IBIO-800 in IND-enabling studies; in-licensed AstralBio amylin receptor program.
Financings: $100M public offering (Aug 2025), $26M private placement (Jan 2026), $100M ATM with Jefferies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.